	US 12,459,984 B2
	Cancer gene therapy drug
Toshiro Shirakawa, Hyogo (JP); Naoto Kunimura, Hyogo (JP); and Koichi Kitagawa, Hyogo (JP)
Assigned to NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, Hyogo (JP)
Appl. No. 17/789,447
Filed by NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, Hyogo (JP)
PCT Filed Dec. 16, 2020, PCT No. PCT/JP2020/046891 § 371(c)(1), (2) Date Jun. 27, 2022, PCT Pub. No. WO2021/131944, PCT Pub. Date Jul. 1, 2021.
Claims priority of application No. 2019-239677 (JP), filed on Dec. 27, 2019.
Prior Publication US 2023/0067359 A1, Mar. 2, 2023
Int. Cl. C07K 14/705 (2006.01); A61K 38/00 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C12N 15/62 (2006.01); C12N 15/86 (2006.01)

CPC C07K 14/70596 (2013.01) [A61P 35/00 (2018.01); C07K 14/47 (2013.01); C07K 14/705 (2013.01); C12N 15/625 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 48/00 (2013.01); C12N 2750/14143 (2013.01)]

20 Claims

1. A nucleic acid having a structure in which (A) a nucleic acid encoding a protein having a CD44 extracellular function, (B) a nucleic acid encoding a protein having a Notch core region function, and (C) a nucleic acid encoding a protein having an HIF-3α4 function are linked in an order of (A)-(B)-(C).